Cited by 317Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEstrogen and related hormone effects

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Burstein, Harold J.·2020·New England Journal of Medicine

Open this paper in CoChat — free account

Abstract

ER-positive, HER2-negative breast cancer, which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy is the cornerstone of systemic therapy, and its efficacy depends on such factors as grade, Ki-67 labeling, and progesterone receptor expression.

Integrity signals

Registry

Crossref · 10.1056/nejmra1307118

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J. B., Kim, W., Cronin, M. T., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,597
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,054

Show all 106 references

Research works printed but not linked: 2

Kalinsky K Barlow WE Meric-Bernstam F et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes hormone receptor positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <25: SWOGS1007 (RxPONDER). Presented at the virtual San Antonio Breast Cancer Symposium December 8–11 2020. abstract.
Mayer EL Gnant M DeMichele A et al. PALLAS: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Presented at the ESMO Virtual Congress September 20 2020. abstract. · DOI

Sorted by citations

Breast Cancer Statistics, 2022
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A. K., Jemal, A., & Siegel, R. L. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,473
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W., Poortmans, P., Regan, M. M., Senn, H.-J., Winer, E. P., Gnant, M. I., Aebi, S. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 875
Self-citation
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 792
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 485
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V. G., Aft, R., Agnese, D. M., Allison, K. H., Anderson, B. M., Burstein, H. J., Chew, H. K., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0031 · Cited by 469
Self-citation
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Bidard, F., Bessard, A. C. H., Dalenc, F., Bachelot, T., Pierga, J., Rouge, T. D. L. M., Sabatier, R., Dubot, C., Frenel, J., Ferrero, J. M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00555-1 · Cited by 381
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Cheng, X. (2024) · Genes · doi:10.3390/genes15070903 · Cited by 258
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Curigliano, G., Burstein, H. J., Gnant, M., Loibl, S., Cameron, D., Regan, M. M., Denkert, C., Poortmans, P. M., Weber, W. P., Thurlimann, B. J. K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.017 · Cited by 264
Self-citation
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02554 · Cited by 235
Self-citation
Therapeutic resistance to anti-oestrogen therapy in breast cancer
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00604-3 · Cited by 182
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
Conforti, F., Pala, L., Sala, I., Oriecuia, C., De Pas, T., Specchia, C., Graffeo, R., Pagan, E., Queirolo, P., Pennacchioli, E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-066381 · Cited by 170
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
Gnant, M., Fitzal, F., Rinnerthaler, G., Steger, G. G., Greil‐Ressler, S., Balić, M., Heck, D., Jakesz, R., Thaler, J., Egle, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104162 · Cited by 161
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 157
Nanoparticle-based materials in anticancer drug delivery: Current and future prospects
Ajith, S., AlMomani, F. A., Elhissi, A. M. A., & Husseini, G. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21227 · Cited by 125
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Bardia, A., Cortés, J., Bidard, F., Neven, P., García-Sáenz, J. Á., Aftimos, P. G., O’Shaughnessy, J., Lu, J. M., Tonini, G., Scartoni, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1073 · Cited by 127
Molecular classification of hormone receptor-positive HER2-negative breast cancer
Jin, X., Zhou, Y.-F., Ma, D., Zhao, S., Lin, C., Xiao, Y., Fu, T., Liu, C., Chen, Y., Xiao, W.-X., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01507-7 · Cited by 118
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
Lindeman, G. J., Fernando, T. M., Bowen, R. L., Jerzak, K. J., Song, X., Decker, T. W., Boyle, F. M., McCune, S., Armstrong, A. C., Shannon, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3811 · Cited by 98
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Meattini, I., Becherini, C., Caini, S., Coles, C. E., Cortés, J., Curigliano, G., de Azambuja, E., Isacke, C. M., Harbeck, N., Kaidar‐Person, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00534-x · Cited by 94
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Martín, M., Lim, E., Chávez‐MacGregor, M., Bardia, A., Wu, J., Zhang, Q., Nowecki, Z. I., Cruz, F. J. S. M., Нурисламович, С. Р., Kim, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01500 · Cited by 83
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
Venetis, K., Pepe, F., Pescia, C., Cursano, G., Criscitiello, C., Frascarelli, C., Mane, E., Russo, G., Salimbeni, B. T., Troncone, G., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102642 · Cited by 71
Endoplasmic reticulum stress targeted therapy for breast cancer
Xu, D., Liu, Z., Liang, M., Fei, Y., Zhang, W., Wu, Y., & Tang, J. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00964-7 · Cited by 69
Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer
Zheng, Z., Xia, L., Hu, G.-S., Liu, J., Hu, Y.-H., Chen, Y.-J., Jia-yin, P., Zhang, W., & Liu, W. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac778 · Cited by 62
Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Cheng, Y., & Liao, J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01041-w · Cited by 61
Accelerating drug development in breast cancer: New frontiers for ER inhibition
Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57
Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor
Gu, J., Zhu, N., Li, H., Zhao, T., Zhang, C., Liao, D.-F., & Li, Q. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00694-5 · Cited by 58
16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer
Ulaner, G. A. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.03.002 · Cited by 51
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
Palmieri, C., Linden, H. M., Birrell, S. N., Wheelwright, S. J., Lim, E., Schwartzberg, L. S., Dwyer, A. R., Hickey, T. E., Rugo, H. S., Cobb, P. W., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00004-4 · Cited by 50
Sex hormones, the anticancer immune response, and therapeutic opportunities
Conforti, F., Pala, L., Mitri, D. D., Catania, C., Cocorocchio, E., Laszlo, D., Ceresoli, G. L., Locatelli, M., Facella, F., Pas, T. M. D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.013 · Cited by 48
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
Conforti, F., Pala, L., Bagnardi, V., Pas, T. M. D., Colleoni, M. A., Buyse, M. E., Hortobágyi, G. N., Gianni, L., Winer, E. P., Loibl, S., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3755 · Cited by 46
Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer
Zhou, J., Cheng-hao, Y., & Cheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.824531 · Cited by 45
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
Lauro, V. D., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Mastro, L. D., Giuliano, M., Puglisi, F., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100629 · Cited by 44
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 47
Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics
Amato, O., Guarneri, V., & Girardi, F. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000991 · Cited by 45
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer
Delaloge, S., Dureau, S., D’Hondt, V., Desmoulins, I., Heudel, P., Duhoux, F. P., Lévy, C., Lerebours, F., Mouret‐Reynier, M., Dalenc, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.014 · Cited by 41
Robust ERα-Targeted Near-Infrared Fluorescence Probe for Selective Hydrazine Imaging in Breast Cancer
Tang, C. C., Tong, H., Liu, B., Wang, X., Jin, Y., Tian, E., & Wang, F. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03395 · Cited by 39
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
Cao, L.-Q., Sun, H., Xie, Y., Patel, H. H., Bo, L., Lin, H., & Chen, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1340764 · Cited by 44
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
Massa, D., Vernieri, C., Nicolè, L., Criscitiello, C., Boissière‐Michot, F., Guiu, S., Bobrie, A., Griguolo, G., Miglietta, F., Vingiani, A., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae178 · Cited by 40
Updates in endocrine therapy for metastatic breast cancer
Manohar, P. M., & Davidson, N. E. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0255 · Cited by 34
Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis
Su, F., Yang, X., Yin, J., Shen, Y., & Tan, L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13778-9 · Cited by 34
Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer
Ring, A., Spataro, M., WICKI, A. N., & Aceto, N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.929893 · Cited by 34
The role of estrogen receptors in intracellular estrogen signaling pathways, an overview
Gui, Z., Shi, W., Zhou, F., Yan, Y., Li, Y., & Xu, Y. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106632 · Cited by 34
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 30
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
Karimaa, M., Riikonen, R., Kettunen, H., Taavitsainen, P., Ramela, M., Chruściel, M., Karlsson, S., Rummakko, P., Simola, O., Wohlfahrt, G., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0115 · Cited by 31
GRPR-targeting radiotheranostics for breast cancer management
D’Onofrio, A., Engelbrecht, S., Läppchen, T., Rominger, A., & Gourni, E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1250799 · Cited by 29
A Coagulation-Related Gene-Based Prognostic Model for Invasive Ductal Carcinoma
Li, J., Du, J., Wang, Y., & Jia, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.722992 · Cited by 28
Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics
Cen, Y., Chen, L., Liu, Z., Lin, Q., Fang, X., Yao, H., & Gong, C. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01352-x · Cited by 25
How we Treat HR-Positive, HER2-Negative Early Breast Cancer
López‐Tarruella, S., Echavarría, I., Jerez, Y., Herrero, B., Casado, S. G., & Martín, M. (2022) · Future Oncology · doi:10.2217/fon-2021-0668 · Cited by 29
Charge Conversion Polymer–Liposome Complexes to Overcome the Limitations of Cationic Liposomes in Mitochondrial-Targeting Drug Delivery
Shueng, P., Yu, L.-Y., Hou, H.-H., Chiu, H., & Lo, C.-L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063080 · Cited by 26
The mevalonate pathway in breast cancer biology
Göbel, A., Riffel, R. M., Hofbauer, L. C., & Rachner, T. D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215761 · Cited by 25
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
Filipits, M., Rudas, M., Singer, C. F., Fitzal, F., Bagó-Horváth, Z., Greil, R., Balić, M., Lax, S., Halper, S., Hulla, W., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100228 · Cited by 25
The Epigenetic Regulation of Nonhistone Proteins by SETD7: New Targets in Cancer
Chiang, C., Yang, H., Zhu, L., Chen, C., Chen, C., Zuo, Y., & Zheng, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.918509 · Cited by 24
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
Antonarelli, G., Salimbeni, B. T., Marra, A., Espósito, A., Locatelli, M., Trapani, D., Pescia, C., Fusco, N., Curigliano, G., & Criscitiello, C. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104148 · Cited by 26
How I treat endocrine-dependent metastatic breast cancer
Gombos, A., Gonçalvès, A., Curigliano, G., Bartsch, R., Kyte, J., Ignatiadis, M., & Awada, A. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100882 · Cited by 25
Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence
Huang, J., Zhang, J., Ang, L., Li, M., Zhao, M., Wang, Y., & Wu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1265520 · Cited by 24
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha
Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23
“The culture conditions for growing tamoxifen-resistant cells should be detailed.”
Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer
Eustace, A. J., Lee, M. J., Colley, G., Roban, J., Downing, T., & Buchanan, P. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.41 · Cited by 22
Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β
Murakami-Nishimagi, Y., Sugimoto, K., Kobayashi, M., Tachibana, K., Kojima, M., Okano, M., Hashimoto, Y., Saji, S., Ohtake, T., & Chiba, H. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01646-z · Cited by 24
Circulating tumor DNA: from discovery to clinical application in breast cancer
Xu, J., Gao, H., Guan, X., Meng, J., Ding, S., Qian, L., & Yi, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355887 · Cited by 26
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23
A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer
Harbeck, N., Burstein, H. J., Hurvitz, S. A., Johnston, S. R. D., & Vidal, G. A. (2022) · Cancer · doi:10.1002/cncr.34161 · Cited by 22
Self-citation
Phytoestrogens, novel dietary supplements for breast cancer
Huang, S., Qi, B., Yang, L., Wang, X., Huang, J., Zhao, Y., Hu, Y., & Xiao, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114341 · Cited by 22
Mechanisms of Traditional Chinese medicine/natural medicine in HR-positive Breast Cancer: A comprehensive Literature Review
Yu, Q., Xu, C., Song, J., Jin, Y., & Gao, X. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117322 · Cited by 20
Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy
Wang, L., Luo, R., Lu, Q., Jiang, K., Hong, R., Lee, K., Zhang, P., Zhou, D., Wang, S., & Xu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.735670 · Cited by 19
Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development
Gautam, N., Ramamoorthi, G., Champion, N., Han, H. S., & Czerniecki, B. J. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101239 · Cited by 19
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Copur, M. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101282 · Cited by 19
Oncotype DX Recurrence Score in premenopausal women
Zhang, S., Fitzsimmons, K. C., & Hurvitz, S. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221081077 · Cited by 18
The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?
da Luz, F. A. C., Araújo, B. J., & de Araújo, R. A. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103781 · Cited by 18
Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer
Xie, T., Zahid, H., Ali, A. R., Joyce, R., Yang, G., Winz, C., Le, Y., Zhou, R., Furmanski, P., Hu, L., et al. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116375 · Cited by 18
Metastasis prevention: targeting causes and roots
Schegoleva, A. A., Khozyainova, A. A., Gerashchenko, T. S., Zhuikova, L. D., & Denisov, E. V. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10162-x · Cited by 19
Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer
Ruscitto, F., Roda, N., Priami, C., Migliaccio, E., & Pelicci, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116271 · Cited by 21
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations
Bielo, L. B., Rocco, E. G., Trapani, D., Zagami, P., Salimbeni, B. T., Esposito, A., Belli, C., Crimini, E., Venetis, K., Munzone, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103731 · Cited by 17
A Tumor Microenvironment-Driven Network Regulated by STAT3 and p65 Negatively Controls the Enrichment of Cancer Stem Cells in Human HR+/HER2− Breast Cancer
Ben-Yaakov, H., Meshel, T., Pasmanik, M., Körner, C., & Ben‐Baruch, A. (2023) · Cancers · doi:10.3390/cancers15082255 · Cited by 18
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
Zhou, F., Yang, G., Xue, L., Liu, Y., Guo, Y., Zhu, J. Y., Yuan, L., Gu, P., Tang, F., Shan, J., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01695-4 · Cited by 17
ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
Betz, M., Massard, V., Gilson, P., Witz, A., Dardare, J., Harlé, A., & Merlin, J. (2023) · Cancers · doi:10.3390/cancers15215169 · Cited by 19
Aromatase Inhibitor Therapy Increases the Risk of New-Onset Atrial Fibrillation in Patients With Breast Cancer
Ho, I., Wong, C., Wong, Y., Lam, T.-H., Leung, I. S. H., Lin, M., Lui, D. T. W., Kwok, W. C., Tam, C. C., Chan, Y., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.09.014 · Cited by 17
Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study
Kim, J. H. (2024) · Cancers · doi:10.3390/cancers16162869 · Cited by 17
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Tarantino, P., Burstein, H. J., Lin, N., Krop, I. E., Winer, E. P., Schnitt, S. J., Hamilton, E. P., Hurvitz, S. A., Rugo, H. S., Curigliano, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.004 · Cited by 17
Self-citation
Development of novel agents for the treatment of early estrogen receptor positive breast cancer
Elliott, M. J., & Cescon, D. W. (2021) · The Breast · doi:10.1016/j.breast.2021.11.007 · Cited by 15
Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway
Liu, C., Li, S., Zhang, X., Jin, C., Zhao, B., Li, L., Miao, Q., Jin, Y. H., & Fan, Z. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00542-6 · Cited by 15
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer
Giacomini, A., Turati, M., Grillo, E., Rezzola, S., Ghedini, G. C., Schuind, A. C., Foglio, E., Maccarinelli, F., Faletti, J., Filiberti, S., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00441-y · Cited by 15
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
Mamann, A., Pradat, Y., Bidard, F., Delaloge, S., Cabel, L., Faull, I., Marques, S., Bachelot, T., Dalenc, F., Rouge, T. D. L. M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.06.015 · Cited by 15
Real-World Outcomes of Elacestrant in ER+, HER2−, ESR1 -Mutant Metastatic Breast Cancer
Rugo, H. S., Kaklamani, V., McArthur, H. L., Wander, S. A., Gradishar, W. J., Mahtani, R. L., Pegram, M. D., Lustberg, M. B., Swallow, E., Maitland, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3040 · Cited by 15
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
Bergqvist, M., Nordmark, A., Williams, A., Paoletti, C., Barlow, W. E., Cobain, E. F., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., et al. (2023) · Biomarkers · doi:10.1080/1354750x.2023.2168063 · Cited by 13
Association of ESR1 gene polymorphisms with the susceptibility to Hepatitis B virus infection and the clinical outcomes
Xie, J., Ding, Y., Li, X., Pu, R., Liu, W., Li, P., & Yin, J. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28510 · Cited by 14
Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs
Watson, J., Wang, T., Ho, K.-L., Yuan, F., Mahawan, T., Dobbin, K. K., & Zhao, S. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01705-5 · Cited by 15
Clinical efficacy of tumor organoid‐guided cancer therapy for locally advanced unresectable or metastatic breast cancer
Lin, Y., Gao, H., Li, H., Hu, Q., Du, B., Li, S., Xu, F., Cheng, M., Zou, J., Zheng, X., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34945 · Cited by 15
Safety of solid oncology drugs in older patients: a narrative review
Rousseau, A., Géraud, A., Geiss, R., Farcet, A., Spano, J., Hamy, A., & Gougis, P. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103965 · Cited by 14
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Arboleda-Osorio, B., Bartsch, R., de Azambuja, E., Hamilton, E. P., Harbeck, N., Klemp, J. R., Knauer, M., Küemmel, S., Mahtani, R. L., Schwartzberg, L. S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac101 · Cited by 14
Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy
Burgermeister, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713661 · Cited by 13
Invasive papillary carcinoma of the breast
Wang, S., Zhang, Q., & Mao, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1374091 · Cited by 13
Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment
Li, J., Zhao, B., Zhu, Y.-Q., & Wu, J. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/5132916 · Cited by 13
Molecular and Pathobiology of Canine Mammary Tumour: Defining a Translational Model for Human Breast Cancer
de Oliveira-Lopes, A. F., Götze, M. M., Lopes-Neto, B. E., Guerreiro, D. D., Bustamante‐Filho, I. C., & Moura, A. A. (2024) · Veterinary and Comparative Oncology · doi:10.1111/vco.12996 · Cited by 14
Estrogen Receptor-α Exacerbates EGF-Inducing Airway Remodeling and Mucus Production in Bronchial Epithelium of Asthmatics
Qin, L., Yue, J., Guo, M., Zhang, C., Fang, X., Zhang, S., Bai, W., Liu, X., & Xie, M. (2023) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2023.15.5.614 · Cited by 12
Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives
Ndlovu, H., Lawal, I. O., Mokoala, K. M. G., & Sathekge, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031575 · Cited by 12
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
McGrath, M. K., Abolhassani, A., Guy, L., Elshazly, A. M., Barrett, J. T., Mivechi, N. F., Gewirtz, D. A., & Schoenlein, P. V. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1298423 · Cited by 13
Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial
Xu, B., Zhang, Q., Luo, Y., Tong, Z., Sun, T., Shan, C., Liu, X., Yao, Y., Zhao, B., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56096-2 · Cited by 14
Opportunities, obstacles and current challenges of flavonoids for luminal and triple-negative breast cancer therapy
Vachetta, V. S., Marder, M., Troncoso, M. F., & Elola, M. T. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100077 · Cited by 12

Authors: Burstein, H. J.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Burstein, Harold J.
ORCID: Burstein, Harold J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-12-24
Volume: 383
Issue: 26
Pages: 2557-2570
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1307118
OpenAlex: W3116128628
Cited by: 316
References: 106
Citations by year: 2026: 51 · 2025: 53 · 2024: 67 · 2023: 62 · 2022: 53 · 2021: 30
FWCI: 3.70
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords: estrogen receptor-positive breast cancer, HER2-negative breast cancer, systemic therapy, antiestrogen therapy, breast cancer heterogeneity, progesterone receptor expression, tumor grade
MeSH terms: Breast Neoplasms, Female, Humans, Prognosis, Receptors, Estrogen, Chemotherapy, Adjuvant, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Neoadjuvant Therapy, Selective Estrogen Receptor Modulators, Estrogen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks